Paroxysmal extreme pain disorder treatment

Abstract

The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

1 - 12 . (canceled) 
     
     
         13 . A method for treating paroxysmal extreme pain disorder, comprising administering to a human subject in need thereof (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof, wherein the subject has been identified as having one or more genetic variations within the CACNA1A gene and/or the CACNA1B gene. 
     
     
         14 . The method of  claim 13 , wherein the (5R)-5-(4-{[(2-fluorophenyl) methyl]oxy}phenyl)-L-prolinamide or the pharmaceutically acceptable salt thereof is (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochloride. 
     
     
         15 . The method of  claim 13 , wherein the (5R)-5-(4-{[(2-fluorophenyl) methyl]oxy}phenyl)-L-prolinamide or the pharmaceutically acceptable salt thereof is (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide sulfuric acid salt. 
     
     
         16 . The method of  claim 13 , wherein the subject has been identified as having one or more genetic variations within the CACNA1A gene. 
     
     
         17 . The method of  claim 16 , wherein the one or more genetic variations within the CACNA1A gene are between 13,300,000 bp and 13,450,000 bp on chromosome 19. 
     
     
         18 . The method of  claim 17 , wherein the one or more genetic variations within the CACNA1A gene are between 13,318,000 bp and 13,412,000 bp on chromosome 19. 
     
     
         19 . The method of  claim 13 , further comprising a step of detecting the presence of one or more genetic variations within the CACNA1A gene and/or the CACNA1B gene of the subject.